Kinjo Kunihiro, Sato Hiroshi, Sakata Yasuhiko, Nakatani Daisaku, Mizuno Hiroya, Shimizu Masahiko, Nishino Masami, Ito Hiroshi, Tanouchi Jun, Nanto Shinsuke, Hori Masatsugu
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.
Am J Cardiol. 2005 Sep 1;96(5):617-21. doi: 10.1016/j.amjcard.2005.04.030.
We evaluated the interaction between inflammation and survival benefit from statin therapy in patients who had acute myocardial infarction. Although 1-year mortality did not differ between patients who used statin therapy and those who did not, among patients who had C-reactive protein (CRP) concentrations in the lower 2 tertiles (<2.9 mg/L), 1-year mortality was higher in patients who used statin therapy than in those who did not within the highest CRP-defined tertile (> or =2.9 mg/L). Statin therapy significantly decreased the hazard ratio for 1-year mortality in patients who had high CRP levels to approximately the hazard present for patients who had low CRP levels and did not receive statin therapy.
我们评估了急性心肌梗死患者炎症与他汀类药物治疗生存获益之间的相互作用。虽然使用他汀类药物治疗的患者与未使用他汀类药物治疗的患者1年死亡率没有差异，但在C反应蛋白（CRP）浓度处于较低三分位数（<2.9 mg/L）的患者中，在CRP定义的最高三分位数（≥2.9 mg/L）内，使用他汀类药物治疗的患者1年死亡率高于未使用他汀类药物治疗的患者。他汀类药物治疗显著降低了高CRP水平患者1年死亡率的风险比，使其降至与低CRP水平且未接受他汀类药物治疗的患者大致相同的风险水平。
